(Albany, New York) – September 11, 2026: DelveInsight’s “Endometriosis Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Endometriosis, historical and forecasted epidemiology as well as the Endometriosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Endometriosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Endometriosis Market Forecast
Some of the key facts of the Endometriosis Market Report:
The Endometriosis market size across the 7MM was valued at approximately USD 1,500 million in 2025 and is projected to grow at a CAGR of 6.2% through 2036.
In September 2026, Cartherics Pty Ltd, a biotechnology company focused on developing off-the-shelf immune cell therapies for high-impact women’s diseases, has announced a research collaboration and option agreement with the Zucker Institute, the commercialization arm of the Medical University of South Carolina (MUSC). Cartherics’ lead programs currently focus on ovarian cancer and endometriosis. Under the agreement, the organizations will investigate the potential of combining Cartherics’ induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor natural killer (CAR-NK) platform with a novel anti-tissue factor antibody developed by researchers at MUSC and the Regina Elena National Cancer Institute. The collaboration aims to explore potential applications of this combination approach in cancer and endometriosis.
As of March 2026, Gesynta Pharma is administering vipoglanstat (GS-248) to the first patient in a new Phase II trial of a revolutionary, non-hormonal treatment for endometriosis. The NOVA trial advances the candidate to mid-stage testing in an area where novel therapeutic approaches that circumvent the adverse effects of hormone-based therapy.
In March 2026, EndoCyclic Therapeutics has received approval from the US FDA for its Investigational New Drug (IND) application for ENDO-205, a potential treatment for endometriosis. Following this clearance, the company plans to begin a Phase I clinical trial in healthy premenopausal women of reproductive age. Endometriosis, a chronic and progressive condition affecting around 10% of females during their reproductive years, is characterized by the growth of tissue similar to the uterine lining outside the uterus.
In November 2025, Hyderabad-based MSN Laboratories Pvt Ltd has received a recommendation from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to begin a Phase IV clinical study for Elagolix Sodium Tablets (150 mg and 200 mg), intended for managing moderate to severe endometriosis-related pain. The decision was made during the SEC meeting on September 18, 2025, at CDSCO headquarters in New Delhi. As part of the post-marketing requirement linked to the drug’s approval, the company submitted its Phase IV trial proposal titled “A Multicentre, Open-Label, Single-Arm Phase IV Clinical Trial to Assess the Safety and Effectiveness of Elagolix Tablets 200 mg for Treatment of Patients with Moderate to Severe Pain Associated with Endometriosis” (Protocol No. 017/MSN/ELGLX/2025, Version 1.0, dated July 3, 2025).
In July 2025, A drug candidate once described by Organon as potentially its “biggest opportunity” failed to meet expectations in a Phase 2 clinical trial, leading the company to discontinue its development for endometriosis. Organon, a women’s health-focused company, had acquired the drug OG-6219 through its $75 million upfront acquisition of Forendo Pharma in 2021. Following the acquisition and in an effort to expand its R&D pipeline after its spinout from Merck & Co., Organon initiated a Phase 2 trial in 2022. However, due to disappointing results, the company has now decided to halt further development of the therapy.
In June 2025, NICE reported a positive recommendation for linzagolix choline (YSELTY) for NHS reimbursement for the symptomatic treatment of endometriosis in women with a history of prior medical or surgical intervention.
In April 2025, ditxt subsidiary Pearsanta received approval from WCG Clinical’s Institutional Review Board (IRB) to initiate a clinical trial for the blood-based Mitomic Endometriosis Test (MET). Designed to aid in the early detection of endometriosis, the study—titled ‘Mitochondrial DNA Deletions in Plasma as a Diagnostic Aid for Females Presenting with Symptoms of Endometriosis’—will evaluate the test’s clinical performance compared to laparoscopic diagnosis.
In April 2025, Aditxt, Inc. (NASDAQ: ADTX), a company focused on advancing impactful health innovations, announced that its subsidiary, Pearsanta, Inc., has secured Institutional Review Board (IRB) approval from WCG Clinical to begin a prospective clinical study. The study will assess the Mitomic® Endometriosis Test (MET), an innovative blood-based diagnostic aimed at supporting the early detection of endometriosis.
In March 2025, England’s NHS is set to offer the first long-term daily pill for endometriosis treatment, following a recommendation by the National Institute for Health and Care Excellence (NICE) in its final draft guidance. The medication, relugolix-estradiol-norethisterone—also known as relugolix combination therapy (relugolix CT)—is approved for adults of reproductive age who have not found relief through prior medical or surgical treatments. This marks the first time the NHS has approved a long-term therapy of this kind for endometriosis. An estimated 1,000 women each year are expected to benefit from this new treatment option.
In July 2025, A drug candidate once described by Organon as potentially its “most significant opportunity” has failed to meet expectations in a Phase 2 clinical trial, leading the company to terminate its development for endometriosis. Organon, a company focused on women’s health, had acquired the investigational therapy OG-6219 through its $75 million upfront acquisition of Forendo Pharma in 2021, shortly after its spinout from Merck & Co.. The Phase 2 trial was launched the following year as part of efforts to expand its R&D pipeline.
In March 2025, The first long-term daily oral treatment for endometriosis has been recommended for regular use by the NHS in England. In its final draft guidance, the National Institute for Health and Care Excellence (NICE) advised that relugolix-estradiol-norethisterone be considered as a treatment option for managing endometriosis symptoms in reproductive-age adults who have not found relief from earlier medical or surgical treatments.
The total number of prevalent cases of endometriosis in the 7MM is ~12 million in 2025, whereas the total number of diagnosed prevalent cases of endometriosis in the 7MM is around ~ 6 million in 2025.
According to DelveInsight’s estimates, in 2025, in the United States, diagnosed prevalent cases of endometriosis are predominantly managed by gynecologists, accounting for 3 million cases in 2025.
In Japan, the age-specific prevalent cases of endometriosis is of 7% for ages 15–19, 26% for 20–29, 33% for 30–39, and 34% for 40–49 years.
In 2025, Stage I (minimal) endometriosis accounted for the largest share of diagnosed prevalent cases across EU4 and the UK (50%), followed by Stage II (mild) disease (24%) and Stage III (moderate) disease (14%). Stage IV (severe) endometriosis represented the smallest proportion of the overall case burden (13%).
Diagnosed prevalent cases of endometriosis in Japan were predominantly managed by gynecologists (600,000 cases), followed by generalists (270,000 cases) and other prescribers (27,000 cases).
Key Endometriosis Companies: Kissei Pharmaceutical/Theramex, Hope Medicine, TiumBio, Viramal, Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others
Key Endometriosis Therapies: Linzagolix choline (YSELTY), Elagolix (ORILISSA), HMI-115, TU2670 (Merigolix), VML-0501, FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others
As per the findings of Yoshino et al. (2022), around 2.6 million women in Japan are impacted by endometriosis.
The Endometriosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Endometriosis pipeline products will significantly revolutionize the Endometriosis market dynamics.
Endometriosis Overview
Endometriosis is a chronic condition in which tissue similar to the lining of the uterus (endometrium) grows outside the uterus, commonly on the ovaries, fallopian tubes, or pelvic lining. This misplaced tissue behaves like normal endometrial tissue—thickening, breaking down, and bleeding with each menstrual cycle—but has no way to exit the body, leading to inflammation, pain, and scar tissue formation. Symptoms often include pelvic pain, painful periods, infertility, and digestive issues. While there is no cure, treatment options such as hormonal therapy, pain relievers, and surgery can help manage symptoms and improve quality of life.
Get a Free sample for the Endometriosis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/endometriosis-market
Endometriosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Endometriosis Epidemiology Segmentation:
The Endometriosis market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Total Prevalent Cases of Endometriosis
Total Diagnosed Prevalent Cases of Endometriosis
Prescriber Pattern-specific Diagnosed Prevalent Cases of Endometriosis
Age-specific Diagnosed Prevalent Cases of Endometriosis
Stage-specific Diagnosed Prevalent Cases of Endometriosis
Download the report to understand which factors are driving Endometriosis epidemiology trends @ Endometriosis Epidemiology Forecast
Endometriosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endometriosis market or expected to get launched during the study period. The analysis covers Endometriosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Endometriosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Endometriosis Therapies and Key Companies
Linzagolix choline (YSELTY): Kissei Pharmaceutical/Theramex
Elagolix (ORILISSA): Abbvie
HMI-115: Hope Medicine
TU2670 (Merigolix): TiumBio
VML-0501: Viramal
FOR 6219: Organon
IW-3300: Ironwood Pharmaceuticals
MT-2990: Mitsubishi Tanabe Pharma Corporation
ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences
Linzagolix (OBE2109): ObsEva/Kissei Pharmaceuticals
OVAREST (leuprorelin oral): SWK/Enteris BioPharma
HMI-115: Bayer/Hope Medicine
TU2670 (NCE-403): Tiumbio
OG-6219: Organon
Quinagolide: Ferring Pharmaceuticals
Linzagolix: ObsEva
Discover more about therapies set to grab major Endometriosis market share @ Endometriosis Treatment Landscape
Endometriosis Market Drivers
Increasing disease awareness and diagnosis: Growing awareness initiatives, improved education, and advocacy are helping increase disease recognition and diagnosis rates.
Rising prevalence and disease burden: The substantial global patient population and the chronic impact of pelvic pain and infertility are driving demand for effective treatment options.
Emergence of novel therapies: Development of oral GnRH antagonists, hormone-based therapies, and other targeted approaches is expanding treatment options.
Growing investment in women’s health: Increased focus on reproductive health, healthcare expenditure, and research is supporting market growth.
Robust clinical pipeline: Ongoing clinical trials and the development of innovative therapies addressing significant unmet needs are expected to create future growth opportunities.
Endometriosis Market Barriers
Long diagnostic delays: Lack of awareness, symptom overlap, and normalization of menstrual pain can delay diagnosis and treatment.
Limited long-term treatment options: Current therapies often focus on symptom management, while recurrence and tolerability issues remain significant challenges.
High treatment costs and access limitations: Novel therapies, specialist consultations, imaging, and surgical procedures can create financial barriers.
Side effects associated with hormonal therapies: Long-term hormonal treatment may be associated with tolerability concerns, affecting patient adherence.
Insufficient research and disease awareness: Underfunding, limited scientific understanding, stigma, and inadequate provider education continue to hinder innovation and timely care.
Scope of the Endometriosis Market Report
Study Period: 2022–2036
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies
Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Endometriosis Unmet Needs, KOL’s views, Analyst’s views, Endometriosis Market Access and Reimbursement
To know more about Endometriosis companies working in the treatment market, visit @ Endometriosis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Endometriosis Market Report Introduction
2. Executive Summary for Endometriosis
3. SWOT analysis of Endometriosis
4. Endometriosis Patient Share (%) Overview at a Glance
5. Endometriosis Market Overview at a Glance
6. Endometriosis Disease Background and Overview
7. Endometriosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Endometriosis
9. Endometriosis Current Treatment and Medical Practices
10. Endometriosis Unmet Needs
11. Endometriosis Emerging Therapies
12. Endometriosis Market Outlook
13. Country-Wise Endometriosis Market Analysis (2022–2036)
14. Endometriosis Market Access and Reimbursement of Therapies
15. Endometriosis Market Drivers
16. Endometriosis Market Barriers
17. Endometriosis Appendix
18. Endometriosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
